Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick R Harrington

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 24, 2015
Hepatitis C Virus RNA Levels During Interferon-Free Combination Direct-Acting Antiviral Treatment in Registrational TrialsPatrick R Harrington, Damon J Deming, Takashi E Komatsu, et al.
Journal of Virology|November 5, 2002
Binding of Norwalk virus-like particles to ABH histo-blood group antigens is blocked by antisera from infected human volunteers or experimentally vaccinated micePatrick R Harrington, Lisa Lindesmith, Boyd Yount, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 30, 2015
Ribavirin Reduces Absolute Lymphocyte Counts in Hepatitis C Virus-Infected Patients Treated With Interferon-Free, Direct-Acting Antiviral RegimensPatrick R Harrington, Russell Fleischer, Sarah M Connelly, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 17, 2024
Independent FDA Analyses of Nirmatrelvir/Ritonavir Resistance in the Phase 2/3 Trials EPIC-HR and EPIC-SRJonathan M O Rawson, Eric F Donaldson, Julian J O'Rear, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 29, 2015
Reply to Merli et alPatrick R Harrington, Russell Fleischer, Sarah M Connelly, et al.
The Journal of Infectious Diseases|September 1, 2007
Dynamics of simian immunodeficiency virus populations in blood and cerebrospinal fluid over the full course of infectionPatrick R Harrington, Mary J Connell, Rick B Meeker, et al.
Journal of Virology|December 26, 2001
Systemic, mucosal, and heterotypic immune induction in mice inoculated with Venezuelan equine encephalitis replicons expressing Norwalk virus-like particlesPatrick R Harrington, Boyd Yount, Robert E Johnston, et al.
Clinical Drug Investigation|January 20, 2017
US FDA Perspective on Elbasvir/Grazoprevir Treatment for Patients with Chronic Hepatitis C Virus Genotype 1 or 4 InfectionSarita D Boyd, LaRee Tracy, Takashi E Komatsu, et al.
Hepatology (Baltimore, Md.)|December 2, 2017
Impact of hepatitis C virus polymorphisms on direct-acting antiviral treatment efficacy: Regulatory analyses and perspectivesPatrick R Harrington, Takashi E Komatsu, Damon J Deming, et al.
Gastroenterology|October 25, 2016
Regulatory Analysis of Effects of Hepatitis C Virus NS5A Polymorphisms on Efficacy of Elbasvir and GrazoprevirTakashi E Komatsu, Sarita Boyd, Adam Sherwat, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 24, 2015
Hepatitis C Virus RNA Levels During Interferon-Free Combination Direct-Acting Antiviral Treatment in Registrational TrialsPatrick R Harrington, Damon J Deming, Takashi E Komatsu, et al.
Journal of Virology|November 5, 2002
Binding of Norwalk virus-like particles to ABH histo-blood group antigens is blocked by antisera from infected human volunteers or experimentally vaccinated micePatrick R Harrington, Lisa Lindesmith, Boyd Yount, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 30, 2015
Ribavirin Reduces Absolute Lymphocyte Counts in Hepatitis C Virus-Infected Patients Treated With Interferon-Free, Direct-Acting Antiviral RegimensPatrick R Harrington, Russell Fleischer, Sarah M Connelly, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 17, 2024
Independent FDA Analyses of Nirmatrelvir/Ritonavir Resistance in the Phase 2/3 Trials EPIC-HR and EPIC-SRJonathan M O Rawson, Eric F Donaldson, Julian J O'Rear, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 29, 2015
Reply to Merli et alPatrick R Harrington, Russell Fleischer, Sarah M Connelly, et al.
The Journal of Infectious Diseases|September 1, 2007
Dynamics of simian immunodeficiency virus populations in blood and cerebrospinal fluid over the full course of infectionPatrick R Harrington, Mary J Connell, Rick B Meeker, et al.
Journal of Virology|December 26, 2001
Systemic, mucosal, and heterotypic immune induction in mice inoculated with Venezuelan equine encephalitis replicons expressing Norwalk virus-like particlesPatrick R Harrington, Boyd Yount, Robert E Johnston, et al.
Clinical Drug Investigation|January 20, 2017
US FDA Perspective on Elbasvir/Grazoprevir Treatment for Patients with Chronic Hepatitis C Virus Genotype 1 or 4 InfectionSarita D Boyd, LaRee Tracy, Takashi E Komatsu, et al.
Hepatology (Baltimore, Md.)|December 2, 2017
Impact of hepatitis C virus polymorphisms on direct-acting antiviral treatment efficacy: Regulatory analyses and perspectivesPatrick R Harrington, Takashi E Komatsu, Damon J Deming, et al.
Gastroenterology|October 25, 2016
Regulatory Analysis of Effects of Hepatitis C Virus NS5A Polymorphisms on Efficacy of Elbasvir and GrazoprevirTakashi E Komatsu, Sarita Boyd, Adam Sherwat, et al.
Pageof 3